CMVLF Stock News Cellectis Romainvil (CMVLF) 18.7600 07/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Jul 13, 2014 at 12:03 PM

Cellectis Romainvil (CMVLF) 18.7600 $CMVLF

Cellectis R&D / Analyst Day
Business Wire - Wed Jun 25, 11:18AM CDT
Regulatory News:

Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding

Cellectis' UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA
Business Wire - Mon Jun 23, 11:14AM CDT
Regulatory News :

Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014
Business Wire - Thu Jun 19, 11:00AM CDT
Dr. David Sourdive, PhD, EVP Corporate Development at Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA) will be attending Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in The Yale Club, New York.

Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration
Business Wire - Wed Jun 18, 12:00AM CDT
Pfizer Inc. (NYSE

FE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis' CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient's own T-cells to target tumor cells).

Cellectis to Present New Data Update on Its Allogeneic CAR T Cell Therapeutics at the 19th Congress of the European Hematology Association (EHA)
Business Wire - Tue Jun 10, 11:00AM CDT
Dr. Julianne Smith, PhD, VP CART Development at Cellectis (Paris:ALCLS) and Dr. Roman Galetto, PhD, Project Leader, will be attending the 19th Congress of the European Hematology Association in Milan, Italy from June 12th to 15th, 2014.

Cellectis enters into an agreement with CELLforCURE for the cGMP manufacturing of allogeneic CART cells
Business Wire - Mon Jun 09, 11:08AM CDT
Regulatory News:

Cellectis and Accelera (Nerviano Medical Sciences Group) Sign an Agreement to Complete Preclinical Studies of Cellectis' Lead Product Candidate UCART19
Business Wire - Thu Jun 05, 11:00AM CDT
Regulatory News:

Cellectis and Thermo Fisher Scientific Enter Into Agreements on TALEN(TM), a Leading Gene Editing Technology
Business Wire - Thu Jun 05, 1:00AM CDT
Regulatory News:

Cellectis plant sciences reports improvement of oil content in algae
Business Wire - Thu May 29, 11:00AM CDT
Regulatory News:

Cellectis will be Present at the ASCO Annual Meeting
PR Newswire - Tue May 27, 11:00AM CDT
André Choulika, PhD, CEO of Cellectis (Alternext: ALCLS) and Mathieu Simon, MD, Executive Vice President will be attending this year's ASCO meeting in Chicago, IL on May the 30th to June 3rd, 2014.

Cellectis Plant Sciences Reports Generation of High Oleic Soybean in Journal of Plant Biotechnology
Business Wire - Fri May 23, 11:40AM CDT
Regulatory News:

TAL-effector Nuclease: The USPTO Issues a Fourth Patent Licensed to Cellectis
Business Wire - Mon May 19, 11:30AM CDT
Regulatory News:

Cellectis Announces the Closing of EUR20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Business Wire - Mon Mar 31, 1:31PM CDT
Regulatory News:

Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors
Business Wire - Mon Feb 17, 1:03PM CST
Regulatory News:

US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases
Business Wire - Wed Feb 05, 11:00AM CST
Regulatory News:

Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models
Business Wire - Tue Feb 04, 11:44AM CST
Regulatory News:

Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing
Business Wire - Thu Jan 30, 12:00AM CST
Regulatory News:

Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays
Business Wire - Fri Jan 17, 11:00AM CST
Regulatory News:

Cellectis Plant Sciences Announce the Finalization of the First Glycosylation Lines of Their Program
Business Wire - Thu Jan 09, 10:59AM CST
Regulatory News :

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Must Decide by Dec 15 Class Suit

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Sinclair Faces Labor Lawsuit for Break-time Violations

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Tennessee's Bold Lung Cancer Trial Signals Innovation

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Air Sealing First: Boosting Home Comfort & Efficiency

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...